Where/What/How we publish
Total number of publications: 101
Journals we published most in:
Highest impact factor journals we have published in:
Our most cited paper (below) has 574 citations (Google Scholar, Jan 2021)!
Clickhere to access all our publications!
Shortlist of Highlighted Publications
- Stille, J.; Tjutrins, J.; Wang, G.; Venegas, F.A.; Hennecker, C.; Rueda, A.M.; Miron, C.E.; Pinus, S.; Labarre, A.; Plescia, J.; Burai Patrascu, M.; Vlaho, D.; Huot, M.; Mittermaier, A.K.; Moitessier, N.; Design, Synthesis and Biological Evaluation of Novel SARS-CoV-2 3CLpro Covalent Inhibitors. ChemRxiv - preprint, 2020 link
- Burai Patrascu, M., Pottel, J., Pinus, S., Bezanson, M., Norrby, P-O., Moitessier, N. From Desktop to Benchtop with Automated Computational Workflows for Computer Aided Design in Asymmetric Catalysis. Nature Catalysis 2020, 3, 574–584. link
- Plescia, J.; Moitessier, N. Design and discovery of boronic acid drugs. Eur. J. Med. Chem. 2020, 112270. link
- Plescia, J.; Dufresne, C.; Janmamode, N.; Wahba, A. S.; Mittermaier, A. K.; Moitessier, N. Discovery of covalent prolyl oligopeptidase boronic ester inhibitors. Eur. J. Med. Chem. 2020, 185, 111783. link
- Plescia, J.; De Cesco, S.; Burai Patrascu, M.; Kurian, J.; Di Trani, J.; Dufresne, C.; Wahba, A. S.; Janmamode, N.; Mittermaier, A. K.; Moitessier, N. Integrated Synthetic, Biophysical, and Computational Investigations of Covalent Inhibitors of Prolyl Oligopeptidase and Fibroblast Activation Protein Alpha. J. Med. Chem. 2019, 62, 7874-7884. link
- Champion C., Barigye, S., Wei W., Liu, Z., Labute, P., Moitessier, N. Atom Type Independent Modeling of the Conformational Energy of Benzylic, Allylic, and other Bonds Adjacent to Conjugated Systems. J. Chem. Inf. Model. 2019, 59, 4750-4763. link
- Luo J., Wei W., Waldisphul J., Moitessier, N. Challenges and current status of computational methods for docking small molecules to nucleic acids. Eur. J. Med. Chem. 2019, 168, 414-425. link
- Malek-Adamian E., Guenther D., Matsuda S., Martínez-Montero S., Zlatev I., Harp J., Burai Patrascu, M., Foster D. J., Fakhoury J. J., Perkins P., Moitessier N., Manoharan R., Taneja N., Bisbe A., Charisse K., Maier M. A., Rajeev K. G., Egli M., Manoharan M., Damha M. J. 4′-C-Methoxy-2′-Deoxy-2′-Fluoro Modified Ribonucleotides Improve Metabolic Stability and Elicit Efficient RNAi-Mediated Gene Silencing. J. Am. Chem. Soc. 2017, 139, 14542–14555. link
- Burai Patrascu, M., Malek-Adamian E., Damha M. J., Moitessier N. Accurately Modeling the Conformational Preferences of Nucleosides. J. Am. Chem. Soc. 2017, 139, 13620–13623. link
- Bezanson M., Tomberg, A., Moitessier N. Fluoride-mediated desulfonylative intramolecular cyclization to fused and bridged bicyclic compounds: A complex mechanism. J. Org. Chem. 2017, 82, 2579–2588. link
- Rocheleau, S., Pottel, J., Huskic, I., Moitessier N. Highly Regioselective Monoacylation of Unprotected Glucopyranoside using Transient Directing-Protecting Groups. Eur. J. Org. Chem. 2017, 646–656. link
- Mariaule G., De Cesco S., Airaghi F., Kurian J., Schiavini P., Rocheleau S., Huskić I., Auclair K., Mittermaier A., Moitessier N. 3-Oxo-hexahydro-1H-isoindole-4-carboxylic acid as a Drug Chiral Bicyclic Scaffold: Structure-based Design and Preparation of Conformationally Constrained Covalent and Non-Covalent Prolyl Oligopeptidase Inhibitors. J. Med. Chem. 2016, 59, 4221–4234.link
- Tomberg A., Pottel J., Liu Z., Labute P., Moitessier N. Understanding P450-mediated Bio-transformations into Epoxide and Phenolic Metabolites. Angew. Chem. Int. Ed. 2015, 54, 13743–13747. link
- Campagna-Slater V., Pottel J., Therrien E., Cantin L.-D., Moitessier N. Development of a computational tool to rival experts in the prediction of sites of metabolism of xenobiotics by P450s. J.Chem.Inf.Model. 2012, 52, 2471-2483. link